Published in J Immunol on April 15, 1991
The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol (1996) 4.45
Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 3.59
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 3.27
Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol (2000) 3.18
Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med (1997) 2.76
Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med (2005) 2.28
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood (2010) 1.88
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med (1996) 1.85
Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A (1998) 1.76
Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J Virol (1992) 1.71
Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J Virol (1994) 1.66
Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol (1997) 1.63
CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med (2005) 1.61
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood (2011) 1.54
Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol (1993) 1.51
Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med (2005) 1.50
Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve. J Immunol (2008) 1.37
Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques. J Virol (1996) 1.31
Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes. J Clin Invest (1993) 1.31
Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions. J Virol (2002) 1.19
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17
Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol (2000) 1.17
Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot" J Transl Med (2005) 1.13
Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding. J Virol (1995) 1.12
Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol (1996) 1.04
Targeted delivery of peptide epitopes to class I major histocompatibility molecules by a modified Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1993) 1.03
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood (2008) 1.01
Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol (2000) 1.00
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood (2012) 0.99
Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19K in the presence of gamma interferon. J Virol (1996) 0.96
Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina. J Clin Invest (1995) 0.94
Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8+ T cells. J Virol (2012) 0.93
A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells. J Med Primatol (2010) 0.92
Gene therapy for infectious diseases. Clin Microbiol Rev (1998) 0.91
Characterization of Haemophilus ducreyi-specific T-cell lines from lesions of experimentally infected human subjects. Infect Immun (2001) 0.90
Simian immunodeficiency virus-specific CD8+ T cells recognize Vpr- and Rev-derived epitopes early after infection. J Virol (2010) 0.89
Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity. Scand J Immunol (2003) 0.85
Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther (2009) 0.85
Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates. J Virol (2001) 0.84
Cell-mediated immunity to human CMV infection: a brief overview. F1000Prime Rep (2014) 0.83
Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes. J Virol (2000) 0.83
Recombinant viruses as tools to study human cytomegalovirus immune modulation. Med Microbiol Immunol (2008) 0.79
Immunization with the immediate-early tegument protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus challenge. J Virol (1993) 0.79
Blood and alveolar lymphocyte subsets in pulmonary cytomegalovirus infection after lung transplantation. BMC Infect Dis (2001) 0.79
CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model. J Immunother (2012) 0.76
Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner. Front Microbiol (2016) 0.75
Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. Antimicrob Agents Chemother (1993) 0.75
Measurement of cytotoxic T lymphocyte activity of human cytomegalovirus seropositive individuals by a highly sensitive coupled luminescent method. Med Microbiol Immunol (2009) 0.75
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods (1990) 6.52
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09
The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol (2000) 6.00
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med (1992) 5.11
Upstream open reading frames as regulators of mRNA translation. Mol Cell Biol (2000) 4.99
Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med (2001) 3.90
T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med (1996) 3.88
Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA (1986) 3.37
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol (1999) 3.33
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32
A cis-acting element within the 5' leader of a cytomegalovirus beta transcript determines kinetic class. Cell (1986) 3.20
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 3.14
A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol (1990) 3.00
Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr (1997) 2.93
Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology (1984) 2.91
Regulation of cytomegalovirus late gene expression: gamma genes are controlled by posttranscriptional events. J Virol (1986) 2.84
Detection and expression of DNA homologous to the tox gene in nontoxinogenic isolates of Corynebacterium diphtheriae. Infect Immun (1983) 2.83
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med (1985) 2.65
Regional mapping of the phenylalanine hydroxylase gene and the phenylketonuria locus in the human genome. Proc Natl Acad Sci U S A (1985) 2.58
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med (1999) 2.58
A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods (1989) 2.53
Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol (1994) 2.50
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med (1981) 2.50
Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J (1992) 2.40
Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audiol (2000) 2.36
Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol (1993) 2.25
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20
Retracted HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest (2000) 2.17
Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature (1996) 2.14
Congenital and perinatal cytomegalovirus infections. Rev Infect Dis (1990) 2.04
Sequence requirements for activation of the HIV-1 LTR by human cytomegalovirus. Virology (1991) 1.99
Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics (1999) 1.96
Human cytomegalovirus pp28 (UL99) localizes to a cytoplasmic compartment which overlaps the endoplasmic reticulum-golgi-intermediate compartment. J Virol (2000) 1.93
CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A (1999) 1.93
Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol (1995) 1.91
Translational control of human cytomegalovirus gp48 expression. J Virol (1991) 1.90
Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis (2001) 1.89
Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus. J Virol (1986) 1.85
Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature (1994) 1.83
Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol (1990) 1.83
Two homoeo box loci mapped in evolutionarily related mouse and human chromosomes. Nature (1985) 1.81
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med (1982) 1.76
Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol (1997) 1.73
Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line. J Virol (1993) 1.71
Inhibition of nascent-peptide release at translation termination. Mol Cell Biol (1996) 1.71
Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol (2003) 1.70
Translational inhibition mediated by a short upstream open reading frame in the human cytomegalovirus gpUL4 (gp48) transcript. J Virol (1993) 1.68
Detection of cytomegalovirus antibody with latex agglutination. J Clin Microbiol (1985) 1.66
Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus. Virus Res (1985) 1.63
Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med (1986) 1.62
Safety of retroviral gene marking with a truncated NGF receptor. Nat Med (2003) 1.60
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58
Translational control by an upstream open reading frame in the HER-2/neu transcript. J Biol Chem (1999) 1.58
Lambda transducing phages for the nalA gene of Escherichia coli and conditional lethal nalA mutations. Mol Gen Genet (1978) 1.54
Coding sequence-dependent ribosomal arrest at termination of translation. Mol Cell Biol (1996) 1.54
Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. J Virol (1998) 1.52
Suggestive linkage of developmental dyslexia to chromosome 1p34-p36. Lancet (1993) 1.51
Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol (1993) 1.51
Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc Natl Acad Sci U S A (1993) 1.50
The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol (2000) 1.49
Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood (1998) 1.49
The molecular epidemiology of three biotypes of Corynebacterium diphtheriae in the Seattle outbreak, 1972-1982. J Infect Dis (1989) 1.49
Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol (2000) 1.47
Translational inhibition by a human cytomegalovirus upstream open reading frame despite inefficient utilization of its AUG codon. J Virol (1995) 1.47
5' end-dependent translation initiation of hepatitis C viral RNA and the presence of putative positive and negative translational control elements within the 5' untranslated region. Virology (1992) 1.45
Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis (1995) 1.42
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Prospects for adoptive T cell therapy. Curr Opin Immunol (1997) 1.38
Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus détente. Immunity (2001) 1.37
Human cytomegalovirus (HCMV) smallest capsid protein identified as product of short open reading frame located between HCMV UL48 and UL49. J Virol (1996) 1.35
Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol (1996) 1.34
Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol (2001) 1.34
Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol (1998) 1.34
Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics (1997) 1.33
Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J Virol (1990) 1.33
Translational inhibition by cytomegalovirus transcript leaders. Virology (1990) 1.32
Early clinical manifestations and intellectual outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr (1987) 1.30
Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol (1991) 1.28
H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28
Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. J Immunol (1981) 1.27
Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology (1996) 1.27
Transformation of Corynebacterium diphtheriae, Corynebacterium ulcerans, Corynebacterium glutamicum, and Escherichia coli with the C. diphtheriae plasmid pNG2. Proc Natl Acad Sci U S A (1987) 1.26
FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med (1989) 1.25
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med (1984) 1.24
Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1997) 1.24
Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J Virol (1999) 1.23
Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol (1986) 1.22
Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol (2001) 1.21
Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol (1996) 1.20
Murine Ly-6 multigene family is located on chromosome 15. Proc Natl Acad Sci U S A (1987) 1.20
Structural and immunological characterization of the intracellular forms of an abundant 68,000 Mr human cytomegalovirus protein. J Gen Virol (1987) 1.20